PR Newswire BiotechOriginal article
Inhibrx's INBRX-106 Nearly Doubles Response Rate and Achieves Interim Median PFS of 9.6 months in Phase 2 HNSCC Study
Phase 2positiveINBRX-106pembrolizumabPositive
AI Analysis
Summary
Inhibrx announced positive Phase 2 results for INBRX-106 combined with pembrolizumab in head and neck squamous cell carcinoma, achieving a 48.3% response rate and interim median PFS of 9.6 months, nearly doubling the response rate compared to pembrolizumab alone. This marks the first OX40 agonist to demonstrate clinical benefit in a randomized study.
Clinical Trial Data
Phase
2
Primary Endpoint
Met
Outcome Details
INBRX-106 plus pembrolizumab achieved 48.3% cORR and 72.4% progression-free at 6 months versus 26.5% cORR and 42.8% progression-free for pembrolizumab alone. Interim median PFS of 9.6 months. First OX40 agonist to demonstrate clinical benefit in randomized study.
Importance:7/10
Sentiment:
0.85
Phase 2HNSCCimmunotherapyOX40 agonistcombination therapypositive data
Read the original article
Published by PR Newswire Biotech on September 8, 2026 11:30 AM